# A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine

> **NCT01689532** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 122 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Sirukumab 100 mg
- **DRUG:** Sirukumab 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01689532
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2016-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01689532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01689532, "A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01689532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*